1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval

Odronextamab Was Filed For FL And DLBCL

 
• By Jessica Merrill

The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.

no
FDA rejected Regeneron's BLAs for odronextamab • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. has been expecting to have its second cancer drug on the market shortly, a key catalyst of an ambitious oncology strategy the company embarked on several years ago. But US Food and Drug Administration approval of the CD20xCD3 bispecific antibody odronextamab for relapsed/refractory follicular lymphoma (FL) and relapsed/refractory diffuse large B cell lymphoma (DLBCL) has been delayed due to the clinical trial requirements for accelerated approval.

Key Takeaways
  • Regeneron received two complete response letters for the two BLAs for odronextamab, which both had 31 March FDA action dates.

The company announced on 25 March that it received two complete response letters (CRLs) for the two biologics license applications...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from Therapy Areas

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.